Duncan I D, Clayton L A
Br J Obstet Gynaecol. 1985 Jul;92(7):762-7. doi: 10.1111/j.1471-0528.1985.tb01462.x.
Twenty-one patients with advanced ovarian carcinoma were treated with a combination of cisplatinum and treosulfan. The overall response rate by clinical and ultrasound assessment was 86%, but ultrasound was less optimistic in assessing 'completeness' of response (48% compared with 67% clinically). The median actuarial survival was 21 months. There was a 54.9% probability of survival at 43 months in those patients with a complete response and a median survival of 15 months in patients with a partial response. The data suggest that while short-term survival may depend upon the extent of residual disease, longer-term survival is determined by response to chemotherapy. The only toxicity of note was haematological.
21例晚期卵巢癌患者接受了顺铂和苏消安联合治疗。通过临床和超声评估的总缓解率为86%，但超声在评估缓解“完全性”方面不太乐观（分别为48%和67%）。中位精算生存期为21个月。完全缓解的患者43个月时的生存概率为54.9%，部分缓解的患者中位生存期为15个月。数据表明，虽然短期生存可能取决于残留疾病的程度，但长期生存由化疗反应决定。唯一值得注意的毒性是血液学毒性。
